NASDAQ:PHAS PhaseBio Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding PhaseBio Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.65 +0.13 (+3.69 %) (As of 09/18/2020 09:35 PM ET) Add Compare Share Today's Range$3.45Now: $3.65▼$3.6650-Day Range$3.17MA: $3.76▼$4.3252-Week Range$2.60Now: $3.65▼$8.49Volume184,600 shsAverage Volume536,187 shsMarket Capitalization$107.10 millionP/E RatioN/ADividend YieldN/ABeta1.57 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate is PB2452, which is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase I clinical trial, as well as developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. The company is also developing PB1046, a fusion protein that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension. The company has an agreement with Viamet Pharmaceuticals Holdings, LLC and Selenity Pharmaceuticals (Bermuda) Ltd. to develop PB6440, a lead development compound for treatment of resistant hypertension. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingPhaseBio Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.25, PhaseBio Pharmaceuticals has a forecasted upside of 290.4% from its current price of $3.65.Amount of Analyst CoveragePhaseBio Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesPhaseBio Pharmaceuticals has received 104 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPhaseBio Pharmaceuticals has received 118 “underperform” votes. (Add your “underperform” vote.)Community SentimentPhaseBio Pharmaceuticals has received 53.15% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about PhaseBio Pharmaceuticals and other stocks. Vote “Outperform” if you believe PHAS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PHAS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPhaseBio Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhaseBio Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PhaseBio Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 13.40% of the stock of PhaseBio Pharmaceuticals is held by insiders.Percentage Held by Institutions62.54% of the stock of PhaseBio Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PhaseBio Pharmaceuticals are expected to grow in the coming year, from ($3.09) to ($2.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PhaseBio Pharmaceuticals is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PhaseBio Pharmaceuticals is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPhaseBio Pharmaceuticals has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.49 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PHAS Previous Symbol CUSIPN/A CIKN/A Webwww.phasebio.com Phone610-981-6500Debt Debt-to-Equity Ratio0.44 Current Ratio3.58 Quick Ratio3.58Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.36 million Price / Sales45.38 Cash FlowN/A Price / Cash FlowN/A Book Value$2.09 per share Price / Book1.75Profitability EPS (Most Recent Fiscal Year)($1.43) Net Income$-39,250,000.00 Net Margins-2,310.60% Return on Equity-124.88% Return on Assets-83.16%Miscellaneous Employees40 Outstanding Shares29,343,000Market Cap$107.10 million Next Earnings Date11/12/2020 (Estimated) OptionableNot Optionable $3.65 +0.13 (+3.69 %) (As of 09/18/2020 09:35 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive PHAS News and Ratings via Email Sign-up to receive the latest news and ratings for PHAS and its competitors with MarketBeat's FREE daily newsletter. PhaseBio Pharmaceuticals (NASDAQ:PHAS) Frequently Asked Questions How has PhaseBio Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)? PhaseBio Pharmaceuticals' stock was trading at $3.13 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PHAS shares have increased by 16.6% and is now trading at $3.65. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of PhaseBio Pharmaceuticals? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for PhaseBio Pharmaceuticals. When is PhaseBio Pharmaceuticals' next earnings date? PhaseBio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020. View our earnings forecast for PhaseBio Pharmaceuticals. How were PhaseBio Pharmaceuticals' earnings last quarter? PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) posted its quarterly earnings data on Tuesday, August, 11th. The company reported ($0.98) EPS for the quarter, missing the Zacks' consensus estimate of ($0.52) by $0.46. PhaseBio Pharmaceuticals had a negative return on equity of 124.88% and a negative net margin of 2,310.60%. View PhaseBio Pharmaceuticals' earnings history. What price target have analysts set for PHAS? 5 Wall Street analysts have issued 1 year target prices for PhaseBio Pharmaceuticals' stock. Their forecasts range from $10.00 to $18.00. On average, they anticipate PhaseBio Pharmaceuticals' share price to reach $14.25 in the next twelve months. This suggests a possible upside of 290.4% from the stock's current price. View analysts' price targets for PhaseBio Pharmaceuticals. Are investors shorting PhaseBio Pharmaceuticals? PhaseBio Pharmaceuticals saw a increase in short interest during the month of August. As of August 14th, there was short interest totaling 3,680,000 shares, an increase of 10.5% from the July 30th total of 3,330,000 shares. Based on an average trading volume of 840,400 shares, the days-to-cover ratio is currently 4.4 days. Currently, 24.9% of the shares of the stock are short sold. View PhaseBio Pharmaceuticals' Short Interest. Who are some of PhaseBio Pharmaceuticals' key competitors? Some companies that are related to PhaseBio Pharmaceuticals include Organogenesis (ORGO), Prothena (PRTA), Pandion Therapeutics (PAND), Fortress Biotech (FBIO), BioSpecifics Technologies (BSTC), Amryt Pharma (AMYT), Puma Biotechnology (PBYI), BioDelivery Sciences International (BDSI), Avedro (AVDR), Akebia Therapeutics (AKBA), Kamada (KMDA), Xenon Pharmaceuticals (XENE), MannKind (MNKD), TherapeuticsMD (TXMD) and BELLUS Health (BLUSF). View all competitors. What other stocks do shareholders of PhaseBio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Viking Therapeutics (VKTX), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Amarin (AMRN), Vaxart (VXRT), Nabriva Therapeutics (NBRV) and Selecta Biosciences (SELB). Who are PhaseBio Pharmaceuticals' key executives? PhaseBio Pharmaceuticals' management team includes the following people: Mr. Jonathan P. Mow, Pres, CEO & Director (Age 55, Pay $678.78k)Mr. John P. Sharp, Chief Financial Officer (Age 55, Pay $548.51k)Dr. John S. Lee, Chief Medical Officer (Age 52, Pay $581.5k)Mr. Kristopher L. Hanson, VP, Head of Legal & Corp. Sec. (Age 48)Mr. Michael B. York, VP of Corp. Devel. & Commercial Strategy (Age 55) When did PhaseBio Pharmaceuticals IPO? (PHAS) raised $66 million in an IPO on Thursday, October 18th 2018. The company issued 5,000,000 shares at a price of $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager. What is PhaseBio Pharmaceuticals' stock symbol? PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS." Who are PhaseBio Pharmaceuticals' major shareholders? PhaseBio Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Bridgeway Capital Management Inc. (0.52%), Sabby Management LLC (0.27%), Charles Schwab Investment Management Inc. (0.14%), Nuveen Asset Management LLC (0.11%), First Trust Advisors LP (0.10%) and Goldman Sachs Group Inc. (0.10%). Company insiders that own PhaseBio Pharmaceuticals stock include Clay Thorp, John P Sharp, Jonathan P Mow, Linda Tufts, Michael York, Nancy J Hutson and Venture Advisors Iii Hatteras. View institutional ownership trends for PhaseBio Pharmaceuticals. Which major investors are selling PhaseBio Pharmaceuticals stock? PHAS stock was sold by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., Sabby Management LLC, Goldman Sachs Group Inc., and Nuveen Asset Management LLC. View insider buying and selling activity for PhaseBio Pharmaceuticals. Which major investors are buying PhaseBio Pharmaceuticals stock? PHAS stock was bought by a variety of institutional investors in the last quarter, including Leap Investments LP, Wedbush Securities Inc., Charles Schwab Investment Management Inc., Bank of America Corp DE, and First Trust Advisors LP. Company insiders that have bought PhaseBio Pharmaceuticals stock in the last two years include Clay Thorp, John P Sharp, Jonathan P Mow, Linda Tufts, Michael York, Nancy J Hutson, and Venture Advisors Iii Hatteras. View insider buying and selling activity for PhaseBio Pharmaceuticals. How do I buy shares of PhaseBio Pharmaceuticals? Shares of PHAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is PhaseBio Pharmaceuticals' stock price today? One share of PHAS stock can currently be purchased for approximately $3.65. How big of a company is PhaseBio Pharmaceuticals? PhaseBio Pharmaceuticals has a market capitalization of $107.10 million and generates $2.36 million in revenue each year. The company earns $-39,250,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. PhaseBio Pharmaceuticals employs 40 workers across the globe. What is PhaseBio Pharmaceuticals' official website? The official website for PhaseBio Pharmaceuticals is www.phasebio.com. How can I contact PhaseBio Pharmaceuticals? PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The company can be reached via phone at 610-981-6500 or via email at [email protected] This page was last updated on 9/21/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
